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OBJECTIVE: To identify the predictive markers associated with chemotherapy sensitivity, especially
those producing pathological complete response (pCR) following neoadjuvant chemotherapy (NACT) in
patients with locally advanced breast cancer.
METHODS: Core needle biopsy of 50 locally advanced breast cancer patients was analysed for his-
topathology, grade, oestrogen receptor, progesterone receptor, HER2, Ki-67, p53, Bcl-2, and BAX before
starting NACT. This was correlated with response to NACT using Response Evaluation Criteria in Solid
Tumours criteria.
RESULTS: The mean tumour reduction rate per chemotherapy cycle was significantly higher in BAX-
positive (p = 0.01) and Bcl-2-negative (p = 0.04) tumours. BAX expression significantly (p = 0.043) corre-
lated with a response of an at least 30% reduction in tumour size post-NACT on multivariate analysis. 
A significant relationship was seen between loss of Bcl-2 expression and pCR on univariate (p = 0.048)
analysis. Overall, all of the above 12 parameters had 30.4% and 28.5% success in predicting clinical com-
plete response and pCR, respectively, by the Cox and Snell formula.
CONCLUSION: Of all parameters examined, only the apoptosis-related genes (Bcl-2 and BAX) seemed
to exert some influence on the response to NACT, and neither by itself was sufficient to predict pCR; how-
ever, 50 patients is not sufficient to simultaneously analyse several predictive markers. [Asian J Surg
2010;33(4):157–67]
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Introduction
Locally advanced breast cancer (LABC) continues to be 
a major and difficult disease to treat, especially in un-
screened populations. LABC represents a heterogeneous
group of tumours ranging from slowly growing neoplasms
to rapidly proliferating and aggressive ones, but without
evidence of distant metastases (M0). The management of
LABC has evolved over the last three decades, and
includes a multidisciplinary approach with neoadjuvant
chemotherapy (NACT), surgery, adjuvant systemic therapy,
and radiotherapy. However, whether a patient responds
to NACT remains unpredictable. Because information on
the drug sensitivity of tumours is often unknown before
treatment initiation, many patients are treated to benefit
only a few. Multiple clinical trials have shown that
patients who achieve a pathological complete response
(pCR) after NACT have improved survival.1 Intensive
research has thus been focused on identification of “pre-
dictive markers” that are associated with chemotherapy
sensitivity, especially those producing pCR. Additionally,
NACT in LABC patients provides the best opportunity to
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assess tumour response in vivo and, thus, tailor the treat-
ment. Various studies have analysed a series of tumour-
related characteristics (such as age, menstrual status,
tumour size, node status, grade, and type of tumour) and
certain biomarkers (such as EgR, PgR, HER2, Ki-67, p53,
Bcl2, BAX, p21, TopoIIα, NF-κB, apoptotic index, tumour
cellularity, mitosis) for predicting response to NACT with
inconsistent results.2
Patients and methods
The present prospective study was carried out in the
Department of Surgical Oncology, Institute of Medical
Sciences, Banaras Hindu University, Varanasi (India)
between August 2006 and December 2008. Patients with
LABC (AJCC Stage IIIA and IIIB)3 were included with
prior informed consent. Those not willing to take part in
the treatment protocol; with a history of prior breast sur-
gery, chemotherapy, radiation therapy, or hormone therapy;
or with metastatic disease (M1) at presentation were not
included in the study.
All patients were confirmed to have invasive breast
cancer by analysis of 14-G to 16-G core needle biopsy. The
core needle biopsy samples were assessed for predictive
markers of response to NACT, including histopathology,
grade, oestrogen receptor (EgR), progesterone receptor
(PgR), HER2, Ki-67, p53, Bcl-2, and BAX, before starting
NACT. All patients with a minimum Karnofsky’s status
of 70 were treated with standard CAF [cyclophosphamide
(600 mg/m2), adriamycin (60 mg/m2), 5-fluorouracil
(600 mg/m2)]/FEC [fluorouracil (500 mg/m2), epirubicin
(100 mg/m2), cyclophosphamide (500 mg/m2)] combina-
tion NACT for two to six cycles. Clinical response was
assessed according to the Response Evaluation Criteria in
Solid Tumours (RECIST) criteria4 and categorized as clini-
cal complete response (CR), partial response (PR), stable
disease (SD), or progressive disease (PD). In addition to
physical examination, an imaging confirmation of the
breast tumour size was obtained in each patient before
starting the first cycle of NACT, and again before surgery
(FEC was given once every 3 weeks, CAF once every 
4 weeks after the last chemotherapy) by an ultrasound or
mammogram. The same imaging modality was used in
the patient both before and after NACT.
Responders were classified as patients who achieved 
at least a 30% reduction in their tumour size post-NACT
and included all those with a CR and PR. The mean breast
tumour reduction rate was calculated as follows: 
(d0 − d1)/d0 × 100, where d0 is the longest diameter before
NACT and d1 is the longest diameter after NACT.
Furthermore, to calculate the mean tumour reduction
rate per chemotherapy cycle, we divided the result obtained
by the number of chemotherapy cycles administered to
the patient.
A Patey type of modified radical mastectomy was under-
taken after completion of NACT followed by adjuvant
radiotherapy. Patients who had no residual invasive cancer
in the breast upon histopathology following NACT were
classified as exhibiting pCR. All EgR/PgR-positive patients
were advised to take 20mg of tamoxifen once a day for 5 years
beginning on the day after the last dose of chemotherapy.
Immunohistochemical analysis of predictive markers of
response (EgR, PgR, HER2, p53, Ki-67, Bcl-2, and BAX)
A breast cancer pathologist interpreted the slides without
knowledge of the clinical outcome of each case. Breast
cancer tissue was obtained from prechemotherapy core
needle biopsy, fixed in 10% neutral buffered formalin for
48 hours, and embedded in paraffin. Serial sections of 
4-micron thickness were obtained from tissue blocks and
processed for immunohistochemical studies after confir-
mation of histopathology and tumour grade.
Slides were then deparaffinized and rehydrated with
descending grades of ethyl alcohol. Immunohistochemistry
staining was performed using the following antibodies:
EgR (BioGenex ER88 prediluted, Clone 1D5, Mouse IgG),
PgR (BioGenex PR88 prediluted, dilution 1:20), HER2
(BioGenex prediluted, Clone CB11, Mouse IgG), Ki-67
(Biogenex Recombinant human Ki67 protein, Clone Ki88,
Mouse Ig G1 kappa), p53 protein (Biogenex Recombinant
wild type p53 protein, Clone D07, Mouse Ig G2b), Bcl-2
(Biogenex Synthetic peptide, Clone bcl2/100, Mouse Ig
G1 kappa), and BAX (Biogenex Polyclonal, Rabbit).
Immunostaining was performed manually while
employing a biotin-streptavidin complex. 3,3-Diamino-
benzidine tetrahydrochloride was used as chromogen,
and sections were counterstained with haematoxylin.
Microwave pretreatment (slides were immersed in a 10-mM
citrated buffer, pH 6.0, at 95°C, 5 min × 3) for antigen
retrieval was carried out prior to incubation with primary
antibody. Positive tissue controls of the breast carcinoma
as well as negative control slides run simultaneously were
used to assess the quality of immunostaining. Immuno-
reactivity was quantified by evaluating a minimum 
■ TEWARI et al ■
158 ASIAN JOURNAL OF SURGERY VOL 33 • NO 4 • OCTOBER 2010
of 1,000 carcinoma cells in randomly selected fields on
histological sections using a high-powered objective lens.
The results for EgR, PgR, and p53 protein were consid-
ered positive when more than 10% of the carcinoma cells
showed nuclear positivity. For the evaluation of HER2
expression, semiquantitative analysis was performed
according to scoring guidelines from the HercepTest
instruction guide. In brief, a score of 0 was given to sec-
tions showing no staining or membrane staining in less
than 10% of tumour cells; 1+ was given to sections show-
ing faint or barely perceptible membrane staining in more
than 10% of tumour cells; 2+ was given to sections showing
weak to moderate complete membrane staining in more
than 10% of tumour cells; and 3+ was given to specimens
showing strong complete membrane staining in more than
10% of tumour cells. Scores of 0, 1+, and 2+ were considered
negative for HER2 overexpression, whereas a score of 3+
was considered as HER2 overexpression. Only membranous
staining intensity and patterns were evaluated as defined
in the guidelines.
The Ki-67 index was calculated as the percentage of
cells demonstrating nuclear Ki-67-positive carcinoma
cells. A Ki-67 index equal to or more than 20% was consid-
ered to be a high level. For Bcl-2 and BAX, positive status
was considered when more than 25% of the carcinoma
cells were positive or when strong to moderate immuno-
staining was observed. Faint to negative immunostaining
was considered negative. A strong correlation was seen
between the percentages of cells positive for stain vs. the
intensity of staining.
Statistical analysis
Statistical analysis of the data were performed using
MedCalc statistical software, version 10.0.1.0 (Mariakerke,
Belgium). The relationship between the tumour reduction
rate per chemotherapy cycle and the different predictive
markers of response (age, tumour size, node status, grade,
type of breast cancer, EgR, PgR, HER2, Ki-67, p53 protein,
Bcl-2, and BAX) was determined by the Mann-Whitney 
U test. This test was also used assess whether the number
of NACT cycles had any effect on net tumour size reduc-
tion. To identify variables independently related to res-
ponse to NACT, logistic regression analysis was performed
using the SPSS version 15 (SPSS, Inc., Chicago, IL, USA).
The Cox and Snell formula was used to determine the per-
centage variation explained by the independent study vari-
ables. Fisher’s exact test (on SPSS) was used to analyse the
relationship between predictive markers and pCR. Results
were considered significant when p was less than 0.05. The
likelihood ratio was used to determine the efficacy of the
model after including the independent study variables com-
pared with the baseline values of the same variables. Mul-
tiple logistic regression analysis was performed to predict
the value of dependent variables on the basis of the known
value of the independent variables used in the model.
Results
There were 50 patients with LABC with an age range of
27–70 years (mean, 47.88 ± 10.12 years) and with a mean
tumour size of 6.8 cm (range: 3–18 cm). All patients were
females with the exception of one. There were no patients
with inflammatory breast cancer (T4d), clinically apparent
supraclavicular/infraclavicular involvement (N3), or inter-
nal mammary lymph node involvement. A total of 39 (78%)
patients had skin involvement (usually direct infiltration
with or without an overlying ulcer) or peau d’orange.
Surgery was performed after NACT in 46 patients. The
Patey type of modified radical mastectomy was the most
common procedure undertaken in 42 (91.3%) patients.
Only two patients underwent conservative breast surgery.
Three patients could not be operated on because they
defaulted after NACT and were lost to follow-up, and one
patient had progressive disease, rendering her inoperable
while on NACT. The mean number of NACT cycles admini-
stered was 3.9. Overall, 39 patients (78%) had an at least 30%
response to NACT, and in 7 patients (14%), no tumour
was clinically apparent after NACT (Table 1, Figure 1).
The effect of NACT on the tumour was assessed by an
ultrasound of the breast in 36 and mammography in the
remaining 16 patients. Interestingly, it was found that 76%
of patients had both EgR- and PgR-negative breast cancer,
and 64% had “triple negative” (i.e. EgR-negative + PgR-
negative + HER2-negative) breast cancer. HER2 was posi-
tive (i.e. had a 3+ score) in only six patients (12%).
The mean tumour reduction rate per chemotherapy cycle
was significantly higher in BAX-positive (p = 0.01) and Bcl-
2-negative (p = 0.04) tumours (Table 2). Logistic regres-
sion analysis revealed that BAX expression significantly
correlated with Responders (p = 0.043) (Table 3). Univariate
analysis of 46 patients whose pathological post-NACT
data were available revealed a significant (p = 0.048) rela-
tionship between loss of Bcl-2 expression and pCR. A total
of 26.1% of Bcl-2-negative patients had pCR vs. 4.3% of
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pCR – no viable cancer; totally infarcted &
hyalinized residual tumour (black arrow)
Figure 1. Response to neoadjuvant chemotherapy (NACT). (A) A patient had pathological complete response to NACT. There was 
a residual 5 cm × 4 cm lump in the breast that was found to have no residual tumour upon histopathology. The photomicrograph
(post-NACT) above shows a completely hyalinised and infarcted residual tissue and adjacent normal area with lymphocytic infil-
trates (Haematoxylin and eosin, 100×). (B) Photomicrograph of another patient who had progressive disease on NACT.
Hypercellularity of the tumour, smudging of the nuclei and frequent mitosis is clearly evident (Haematoxylin and eosin, 400×).
Bcl-2-positive patients. The difference, however, was in-
significant upon multivariate analysis (Table 4). The num-
ber of chemotherapy cycles administered did not affect
the outcome (p = 0.0845) in our study (Figure 6).
Overall, all of the above 12 parameters had 30.4%, 29%,
and 28.5% success in predicting CR, CR + PR (Responders),
and pCR, respectively, by the Cox and Snell formula. 
The immunoperoxidase-stained microphotographs of the
predictive markers are depicted in Figures 2–5.
Discussion
This study reports data from a cohort of 50 LABC
patients (mean age, 47.8 years) with a mean tumour size
of 6.8 cm (range: 3–18 cm) and treated by a multimodal
approach. We examined the efficacy of biomarkers (EgR,
PgR, HER2, Ki-67, p53, Bcl-2, and BAX) and clinicopatho-
logical parameters (age, tumour size, node status, grade,
and type of tumour) in predicting response to NACT. The
mean number of preoperative chemotherapy cycles was
3.9. Generally, chemotherapy was given until the patients
were downstaged sufficiently, and this was often achieved
in three to four cycles. A great heterogeneity exists regard-
ing the number of chemotherapy cycles administered in
the neoadjuvant setting, ranging from a fixed number of
three to four cycles to a more flexible number (i.e. until best
clinical response).5,6 Few studies have suggested that
patients who do not show a response after two to three
cycles of NACT are unlikely to do so with continuous
additional cycles of the same regimen,7 and may benefit
from switching to noncross-resistant regimen, although
the reported data are inconsistent.8–11 Following the
RECIST criteria, we found that a CR occurred in 7 (14%)
of the 50 patients subjected to NACT. One patient had 
a residual 5 cm × 4 cm breast lump (thus, clinically PR),
but it turned out to be a case of pCR. Final histopathol-
ogy revealed a complete absence of all invasive and in situ
cancer in the breast and axilla in two patients, only resi-
dual in situ cancer in the breast with a clear axilla in another
two patients, and no invasive or in situ cancer in the breast
but residual invasive cancer in axilla in three patients. 
All seven of these patients with no invasive cancer in the
breast were referred to as those having a pCR in this study.
Of the various predictive markers reported in the litera-
ture,2 only EgR and PgR expressions have been consistently
Table 1. Neoadjuvant chemotherapy (NACT) and response
NACT No. of patients
No. of cycles
2 8
3 11
4 18
5 3
6 10
Response (RECIST)
CR 7
PR 32
SD 7
PD 4
RECIST = response evaluation criteria in solid tumours; CR = complete
response; PR = partial response; SD = stable disease; PD = progressive
disease.
correlated with response to NACT.9,12–16 The literature is
flooded with numerous individual studies that are in favour
of one or more of the above markers. This is interesting,
especially because 64% of our patients had triple-negative,
and 76% had ER-negative and PgR-negative, breast cancer.
Thus, the most frequently studied markers in the current
literature, that is EgR, PgR, and HER2, seemed to have
less influence on decision-making in our context. A much
larger cohort of patients will be needed to elucidate the
difference, if any, between EgR, PgR, and HER2 expres-
sion and response to NACT in our patients.
Because only seven patients had a pCR in our study.
We calculated the mean tumour reduction rate to assess
the overall response to NACT and correlate it with the
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Table 2. Relationship between tumour reduction rate and the following clinicopathological parameters and biomarkers
Parameter No. of patients Mean tumour reduction rate/cycle ± SD p
Age (yr)
≤ 50 34 13.18 ± 12.73 NS
> 50 16 14.98 ± 5.85
Tumour size (cm)
2–5 10 19.54 ± 9.45 NS
> 5 40 12.31 ± 10.95
Node status
N0 or N1 25 13.92 ± 10.04 NS
N2 25 13.59 ± 12.03
Grade
I or II 28 14.65 ± 10.64 NS
III 22 12.62 ± 11.53
Type*
IDC 49 13.91 ± 11.03 –
ILC 1 6.25
EgR
Positive 10 11.76 ± 6.73 NS
Negative 40 14.25 ± 11.81
PgR
Positive 8 11.36 ± 07.06 NS
Negative 42 14.21 ± 11.58
HER2
Positive 6 16.39 ± 8.59 NS
Negative 44 13.40 ± 11.29
Ki-67
Positive 8 16.98 ± 6.44 NS
Negative 42 13.14 ± 11.59
p53
Positive 27 12.54 ± 10.76 NS
Negative 23 15.18 ± 11.29
Bcl-2
Positive 25 10.48 ± 10.03 0.04
Negative 25 17.03 ± 11.08
BAX
Positive 28 15.98 ± 11.15 0.01
Negative 22 10.93 ± 10.30
*One patient had features of both IDC and ILC but was grouped with IDC because it was the dominant histological type. IDC = invasive ductal
carcinoma; ILC = invasive lobular carcinoma; NS = not significant; EgR = oestrogen receptor; PgR = progesterone receptor.
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Figure 2. Immunoperoxidase staining (IP) for oestrogen and progesterone receptors. (A) Oestrogen receptor: tumour cell nuclei
showing no brown staining (IP, 400×). (B) Oestrogen receptor: almost all tumour nuclei are showing strong brown positive staining
(IP, 400×). (C) Progesterone receptor: tumour cell nuclei showing no brown staining (IP, 400×). (D) Progesterone receptor: almost
all tumour nuclei are showing strong brown positive staining (IP, 400×).
Table 3. Correlation of tumour response to neoadjuvant chemo-
therapy (as per RECIST criteria) with the following parameters
Parameter
Responders 
CR (p)
(CR + PR) (p)
Age (yr) NS NS
Tumour size (cm) NS NS
Node status NS NS
Grade NS NS
Type NS NS
EgR NS NS
PgR NS NS
HER2 NS NS
Ki-67 NS NS
p53 NS NS
Bcl-2 NS NS
BAX 0.043 NS
RECIST = response evaluation criteria in solid tumours; CR = complete
response; PR = partial response; EgR = oestrogen receptor; PgR =
progesterone receptor.
Table 4. Correlation of predictive markers with pathological
complete response (pCR) in 46 patients
pCR pCR pCR
Parameter univariate likelihood multivariate 
(p) ratio (p)
Age (yr) 0.465 0.632 NS
Tumour size (cm) 0.714 0.972 NS
Node status 0.480 0.690 NS
Grade 0.848 0.995 NS
Type 0.601 0.632 NS
EgR 0.156 0.500 NS
PgR 0.348 0.835 NS
HER2 0.221 0.046 NS
Ki-67 0.648 0.558 NS
p53 0.350 0.483 NS
Bcl-2 0.048 0.012 NS
BAX 0.078 0.252 NS
EgR = oestrogen receptor; PgR = progesterone receptor.
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Figure 3. Immunoperoxidase staining (IP) for HER2 receptors.
(A) Malignant cells show no membrane staining and are nega-
tive for HER2 (IP, 400×). (B) Weak positive brown staining of
most of the tumour cell membrane (IP, 400×). (C) Strong posi-
tive membrane staining of tumour cell membrane (IP, 400×)
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Figure 4. Immunoperoxidase staining for Ki-67 and p53. (A) Ki-67: tumour nuclei showing no staining (IP, 400×). (B) Ki-67: tumour
nuclei showing strong brown staining (IP, 400×). (C) p53: tumour cell nuclei showing no brown staining (IP, 400×). (D) p53: tumour
nuclei showing strong brown staining (IP, 400×).
predictive markers in each of the 50 patients. The results
indicated a trend toward a better response in patients
older than 50 years, with a tumour of < 5 cm, and with
invasive ductal carcinoma.
We found some interesting results from the 12 predic-
tive markers that we studied. A significant correlation was
found between loss of Bcl-2 expression and pCR upon
univariate analysis (p = 0.048). In addition, loss of Bcl-2
expression (p = 0.04) and BAX expression (p = 0.01) were
associated with a significantly higher mean tumour
reduction rate per chemotherapy cycle. In addition, BAX
was found to correlate significantly with Responders 
(i.e. CR + PR) (p = 0.043) on multivariate analysis. Both
Bcl-2 and BAX belong to the Bcl-2 family of proteins.
Bcl-2 is mainly involved in inhibiting apoptosis, while
BAX functions closely with Bcl-2, but in an opposite manner
as a pro-apoptotic agent. Hence, it has been hypothesized
that either an elevation in Bcl-2 or a reduction in BAX may
predispose to enhanced resistance to chemotherapeutic
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Figure 5. Immunoperoxidase staining for Bcl-2 and BAX. (A) Bcl-2: tumour cell cytoplasm showing weak and patchy brown staining
(IP, 400×). (B) Bcl-2: cell cytoplasm of most of the tumour cells showing strong brown staining (IP, 400×). (C) BAX: moderate stain-
ing of tumour cell cytoplasm (IP, 400×). (D) BAX: strong brown staining of cytoplasm of malignant cells (IP, 400×).
Figure 6. Data comparison graph of the results of the 
Mann-Whitney test showing that the number of neoadjuvant
chemotherapy cycles (NAC) had no effect on net tumour size
reduction. NS = not significant.
drugs. Ogston et al17 reported that upon multivariate
analysis in their study, only an absence of detectable Bcl-2
predicted a better pathological response (p = 0.001).
Similar findings were also reported by other studies.18,19
Expression of BAX is p53-dependent in certain cells, and
is induced by chemotherapeutic drugs and γ-radiation.20
Mutated p53 and the relative ratio of Bcl-2 and BAX, espe-
cially the latter, have been proposed to determine the ulti-
mate sensitivity or resistance of cells to chemotherapy or
radiation, although conflicting reports have come up in
the literature every now and then.17,19,21–27 Krajewski et al28
examined the BAX levels in primary tumours of 119
patients with metastatic breast cancer. A total of 34% of
cases had a < 10% positivity for BAX. The subgroup of
patients with low BAX expression tended not to respond
to chemotherapy (21% vs. 43%; p < 0.02), and generally
experienced a significantly shorter time to tumour pro-
gression and a shorter OS. Such findings have led the
authors to state that women with BAX-negative tumours
might benefit from more aggressive therapy. However,
Buchholz et al19 reported that 11 of the 82 patients (13%) in
their study had a pCR to anthracycline-based chemo-
therapy. Patients with positive staining for Bcl-2, BAX, or
NF-κB less commonly achieved a pCR to chemotherapy
than did those with negative tumour staining. The pCR
rates were NF-κB-positive in 0 (0/13) vs. NF-κB-negative
13% (11/69; p = 0.130); Bcl-2-positive 4% (2/49) vs. Bcl-
2-negative in 27% (9/33; p = 0.004); and BAX-positive 6%
(4/69) vs. BAX-negative 58% (7/12; p < 0.001). Thus, they
concluded that nuclear localization of NF-κB correlates
with Bcl-2 and BAX expression, and that this pathway
may be associated with a poor response to doxorubicin-
based NACT.
BAX expression has been correlated with good responses
in other cancers as well. Chang et al29 evaluated several
markers in pretreatment biopsy samples of 130 rectal carci-
nomas and compared the expressions of these molecular
markers with the pathological responses of the tumours
after therapy. The authors found that BAX expression was
exclusively related to tumour regression. Its expression
was significantly higher in the CR group compared with
the PR group (54% vs. 29%, p = 0.017), and they concluded
that BAX may serve as a predictable molecular marker for
chemoradiosensitivity in rectal carcinoma.
In addition, in our study, three of the four (75%) patients
who progressed on NACT were p53-positive. Such a dis-
tribution of these apoptotic markers in two extreme
response groups indicates their possible role in the even-
tual response to NACT, and this should be tested in trials
involving a large number of patients. According to a very
recent study from the MD Anderson Cancer Center,30
mutant p53 signatures and expression of EgR-related
genes were found to be associated with lower sensitivities
to chemotherapy in EgR-positive breast tumours only. 
A similar association has not been seen among EgR-negative
tumours, which suggests that p53 dysregulation may
have different consequences on chemotherapy sensitivity
depending on the hormone receptor status of the tumour.
This may partly explain the conflicting results regarding
the role of p53 mutation in chemotherapy response in the
literature. This also suggests that p53-mediated apoptosis
may be more important in EgR-positive (luminal) than in
EgR-negative (basal-like) cells. In addition, they stated
that a commonly used proliferation marker, Ki-67, which
was included in the signature, showed no significant over-
expression when tested alone. This is significant because
expression of Ki-67 detected by immunohistochemistry
has shown variable results when correlated with response
to NACT.31–35 We, too, did not find any significant corre-
lation between tumour response and Ki-67.
Rody et al36 found in their German Preoperative
Adriamycin and Docetaxel Study III (GEPARTRIO) trial
that HER2 gene expression was strongly predictive of pCR
(p = 0.017) as well as overall response (p = 0.037) and CR
(p = 0.050). However, Petit et al31 stated that HER2 status
was not related to either the clinical or radiological tumour
response, or to the pathological response with neoadju-
vant FEC (epirubicin dose, 100 mg/m2), thereby refuting
their own earlier publication that high-dose anthracycline
and HER2 overexpression predicted a high overall response
rate.37 HER2 expression did not seem to predict pCR in
our study; furthermore, ILC appeared more resistant to
NACT than to IDC. The literature also reveals ILC to be
significantly more resistant to NACT than to IDC.38–40
The small sample size of our patients in these subsets
must be considered before interpreting the results. All
patients except one in our study had IDC. In addition,
one had features of both IDC and ILC, but was grouped
with IDC for analysis. Similarly, we had only six patients
with HER2 scores of 3+. We included only unambiguous
patients with HER2 scores as positives and thus excluded
all who had HER2 scores of 2+.
The Cox and Snell formula was used to determine the
percentage variation explained by the independent study
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variables (i.e. age, tumour size, node status, grade, type,
EgR, PgR, HER2, Ki-67, p53, Bcl-2, and BAX) and found
that overall, these factors are likely to have only about 29%
success in predicting pCR, CR or at least PR. Hence, none
of these parameters are by themselves sufficient to predict
the response to NACT. Most predictive markers are costly
and difficult to assay, and it appears that the future may
lie in genomic profiling of breast cancer to predict the
response to NACT.
In conclusion, apoptosis-related genes (Bcl-2 and
BAX) seemed to influence the response to NACT; admit-
tedly, however, 50 patients are not sufficient to simulta-
neously analyse several predictive markers. Another
aspect that may be criticized is that immunohistochem-
istry is not the best method of detecting HER2 overex-
pression or p53 mutation, and this may be the reason why
more significant results were not achieved. Moreover, per-
forming numerous tests is not cost-effective. Hence,
much work needs to be done to develop a sensitive, spe-
cific, and practical predictive marker, and this is only pos-
sible through large, multicentre clinical trials because
individual studies with a small sample of patients remain
inconclusive. The answer may lie in the genomic profiling
of breast cancer.
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